Synthesis of MoS₂-TiO₂ nanocomposite for enhanced photocatalytic and photoelectrochemical performance under visible light irradiation

In this work, we have prepared MoS2 nanoflakes modified TiO2 nanoparticles (MoS2-TiO2 nanocomposite) with varying concentration of MoS2 (2.5–10 wt.%) by a two-step hydrothermal synthesis method involving specific preparation conditions for the TiO2 nanoparticles and MoS2 nanoflakes. The prepared samples were characterized by X-ray diffraction (XRD), Raman spectroscopy, scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersive X-ray analysis (EDX), and X-ray photoelectron spectroscopy (XPS) techniques. The photocatalytic activity of the pristine TiO2 nanoparticles and MoS2-TiO2 nanocomposite samples were evaluated by examining the photocatalytic degradation of Rhodamine B (RhB). The photoelectrochemical activity of these samples were measured by performing solar water splitting experiments under visible light irradiation. It was observed that the MoS2-TiO2 nanocomposite with 7.5 wt.% MoS2 exhibits highest photocatalytic and photoelectrochemical activity as it has the optimum amount of MoS2 nanoflakes which probably minimizes the recombination of photogenerated charge carriers as compared to other concentrations of MoS2 in MoS2-TiO2 nanocomposite and pristine TiO2 nanoparticles. In addition, a rather high photocatalytic reaction rate constant was observed for MoS2-TiO2 nanocomposite with 7.5 wt.% MoS2 nanoflakes

Improved photoelectrochemical properties of TiO₂-graphene nanocomposites: Effect of defect induced visible light absorption and graphene conducting channel for carrier transport

Use of heterojunctions between two materials having favorable optical and electronic properties can lead to increased photon absorption and charge separation resulting in enhanced photo-electro-chemical energy conversion. In the present study, graphene monolayer nano-flakes are mixed with TiO2 nanoparticles to form nanocomposites having different weight percentages of graphene. The microstructural, morphological and structural properties of the composite samples are investigated using X-ray diffraction, Raman spectroscopy and transmission electron microscopy techniques. Raman studies carried out on samples annealed at different temperatures show the interfacial interaction between TiO2 and graphene, although Anatase TiO2 and graphene maintain their phase integrity. PEC measurements show higher photo-electro-chemical activity in TiO2-graphene nanocomposite at an optimized concentration (2.0 weight percent) due to increased surface area, higher optical absorption in the visible part of the solar spectrum and favorable carrier transport due to increased concentration of defect states and graphene acting as a charge carrier medium

Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial.

Importance Continuous positive airway pressure (CPAP) and high-flow nasal oxygen (HFNO) have been recommended for acute hypoxemic respiratory failure in patients with COVID-19. Uncertainty exists regarding the effectiveness and safety of these noninvasive respiratory strategies. Objective To determine whether either CPAP or HFNO, compared with conventional oxygen therapy, improves clinical outcomes in hospitalized patients with COVID-19-related acute hypoxemic respiratory failure. Design, Setting, and Participants A parallel group, adaptive, randomized clinical trial of 1273 hospitalized adults with COVID-19-related acute hypoxemic respiratory failure. The trial was conducted between April 6, 2020, and May 3, 2021, across 48 acute care hospitals in the UK and Jersey. Final follow-up occurred on June 20, 2021. Interventions Adult patients were randomized to receive CPAP (n = 380), HFNO (n = 418), or conventional oxygen therapy (n = 475). Main Outcomes and Measures The primary outcome was a composite of tracheal intubation or mortality within 30 days. Results The trial was stopped prematurely due to declining COVID-19 case numbers in the UK and the end of the funded recruitment period. Of the 1273 randomized patients (mean age, 57.4 [95% CI, 56.7 to 58.1] years; 66% male; 65% White race), primary outcome data were available for 1260. Crossover between interventions occurred in 17.1% of participants (15.3% in the CPAP group, 11.5% in the HFNO group, and 23.6% in the conventional oxygen therapy group). The requirement for tracheal intubation or mortality within 30 days was significantly lower with CPAP (36.3%; 137 of 377 participants) vs conventional oxygen therapy (44.4%; 158 of 356 participants) (absolute difference, -8% [95% CI, -15% to -1%], P = .03), but was not significantly different with HFNO (44.3%; 184 of 415 participants) vs conventional oxygen therapy (45.1%; 166 of 368 participants) (absolute difference, -1% [95% CI, -8% to 6%], P = .83). Adverse events occurred in 34.2% (130/380) of participants in the CPAP group, 20.6% (86/418) in the HFNO group, and 13.9% (66/475) in the conventional oxygen therapy group. Conclusions and Relevance Among patients with acute hypoxemic respiratory failure due to COVID-19, an initial strategy of CPAP significantly reduced the risk of tracheal intubation or mortality compared with conventional oxygen therapy, but there was no significant difference between an initial strategy of HFNO compared with conventional oxygen therapy. The study may have been underpowered for the comparison of HFNO vs conventional oxygen therapy, and early study termination and crossover among the groups should be considered when interpreting the findings. Trial Registration isrctn.org Identifier: ISRCTN16912075